Does the efficacy of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor differ according to the type of EGFR mutation in non-small cell lung cancer?
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Many retrospective and prospective studies, as well as meta- analyses including patients with NSCLC with various lines of EGFR TKI treatment, have demonstrated longer progression-free survival and sometimes more favorable overall survival in patients with an exon 19 deletion than those with the L858R or other mutations. In contrast, some clinical studies, including phase III trials, have demonstrated no difference in the efficacy of EGFR TKIs according to the EGFR mutation type. Therefore, the existence of clinically significant differences in sensitivity to EGFR-TKIs among different EGFR mutation subtypes remains controversial. In this review, we summarize the evidence suggesting different outcomes according to the type of EGFR mutation in patients with advanced NSCLC who were treated with EGFR-TKIs, along with their clinical significance. We also discuss possible mechanisms that can explain the different sensitivities to EGFR TKIs between cases with an exon 19 deletion and those with the L858R mutation.
Abstract
An exon 19 deletion and a L858R mutation in exon 21 of the epidermal growth factor receptor (EGFR) are the two most common mutations that predict favorable efficacy of EGFR tyrosine kinase inhibitors (TKIs) in patients with non-small cell lung cancer (NSCLC). Many retrospective and prospective studies, as well as meta- analyses including patients with NSCLC with various lines of EGFR TKI treatment, have demonstrated longer progression-free survival and sometimes more favorable overall survival in patients with an exon 19 deletion than those with the L858R or other mutations. In contrast, some clinical studies, including phase III trials, have demonstrated no difference in the efficacy of EGFR TKIs according to the EGFR mutation type. Therefore, the existence of clinically significant differences in sensitivity to EGFR-TKIs among different EGFR mutation subtypes remains controversial. In this review, we summarize the evidence suggesting different outcomes according to the type of EGFR mutation in patients with advanced NSCLC who were treated with EGFR-TKIs, along with their clinical significance. We also discuss possible mechanisms that can explain the different sensitivities to EGFR TKIs between cases with an exon 19 deletion and those with the L858R mutation.
참고문헌 (39)
- 정규원, "Prediction of Cancer Incidence and Mortality in Korea, 2014", Cancer Research and Treatment, 46(2), pp.123~130 (2014), 대한암학회
- Siegel R, "Cancer statistics, 2014", CA Cancer J Clin, 64, pp.9~29 (2014)
- Jett JR, "Treatment of small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines", Chest, 143(5 Suppl), pp.e400S~e419S (2013)
- Spira A, "Multidisciplinary management of lung cancer", N Engl J Med, 350, pp.379~392 (2004)
- Schiller JH, "Comparison of four chemotherapy regimens for advanced non-smallcell lung cancer", N Engl J Med, 346, pp.92~98 (2002)
- Choi YW, "Is fourth-line chemotherapy routine practice in advanced non-small cell lung cancer?", Lung Cancer, 87, pp.155~161 (2015)
- Reck M, "Metastatic nonsmall-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up", Ann Oncol, 25(Suppl 3), pp.iii27~iii39 (2014)
- 장태원, "EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung", The Korean Journal of Internal Medicine, 24(1), pp.48~54 (2009), 대한내과학회
- Lynch TJ, "Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib", N Engl J Med, 350, pp.2129~2139 (2004)
- Paez JG, "EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy", Science, 304, pp.1497~1500 (2004)
- Maemondo M, "Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR", N Engl J Med, 362, pp.2380~2388 (2010)
- Mitsudomi T, "Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial", Lancet Oncol, 11, pp.121~128 (2010)
- Yang JC, "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6):analysis of overall survival data from two randomised, phase 3 trials", Lancet Oncol, 16, pp.141~151 (2015)
- 이상화, "Analysis of Mutations in Epidermal Growth Factor Receptor Gene in Korean Patients with Non-small Cell Lung Cancer: Summary of a Nationwide Survey", Journal of Pathology and Translational Medicine, 49(6), pp.481~488 (2015), 대한병리학회[DOI]
- Carey KD, "Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib", Cancer Re, 66, pp.8163~8171 (2006)
- Jackman DM, "Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib", Clin Cancer Res, 12, pp.3908~3914 (2006)
- Riely GJ, "Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib", Clin Cancer Res, 12(3 Pt 1), pp.839~844 (2006)
- Sun JM, "The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients", J Cancer Res Clin Oncol, 137, pp.687~694 (2011)
- Won YW, "Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations", J Clin Pathol, 64, pp.947~952 (2011)
- Lee VH, "Association of exon 19 and 21 EGFR mutation patterns with treatment outcome after first-line tyrosine kinase inhibitor in metastatic nonsmall-cell lung cancer", J Thorac Oncol, 8, pp.1148~1155 (2013)
- Rosell R, "Screening for epidermal growth factor receptor mutations in lung cancer", N Engl J Med, 361, pp.958~967 (2009)
- Kim DW, "A multicenter phase II study to evaluate the efficacy and safety of gefitinib as first-line treatment for Korean patients with advanced pulmonary adenocarcinoma harboring EGFR mutations", Lung Cancer, 71, pp.65~69 (2011)
- Igawa S, "Comparison of the efficacy of gefitinib in patients with non-small cell lung cancer according to the type of epidermal growth factor receptor mutation", Oncology, 87, pp.215~223 (2014)
- Asahina H, "A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations", Br J Cancer, 95, pp.998~1004 (2006)
- Sequist LV, "First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations", J Clin Oncol, 26, pp.2442~2449 (2008)
- Sugio K, "Prospective phase II study of gefitinib in non-small cell lung cancer with epidermal growth factor receptor gene mutations", Lung Cancer, 64, pp.314~318 (2009)
- Inoue A, "Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations", J Clin Oncol, 24, pp.3340~3346 (2006)
- Wang H, "Different efficacy of EGFR tyrosine kinase inhibitors and prognosis in patients with subtypes of EGFR-mutated advanced non-small cell lung cancer: a meta-analysis", J Cancer Res Clin Oncol, 140, pp.1901~1909 (2014)
- Zhang Y, "Patients with exon 19 deletion were associated with longer progression-free survival compared to those with L858R mutation after firstline EGFR-TKIs for advanced non-small cell lung cancer:a meta-analysis", PLoS One, 9, pp.e107161~ (2014)
- Lee CK, "Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis", J Clin Oncol, 33, pp.1958~1965 (2015)
- Sheng M, "Comparison of clinical outcomes of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations after tyrosine kinase inhibitors treatment:a meta-analysis", Eur J Clin Pharmacol, 72, pp.1~11 (2016)
- Yong Won Choi, "EGFR Exon 19 Deletion is Associated With Favorable Overall Survival After First-line Gefitinib Therapy in Advanced Non–Small Cell Lung Cancer Patients", American Journal of Clinical Oncology, pp.1~ (2017), Ovid Technologies (Wolters Kluwer Health)[DOI]
- Mulloy R, "Epidermal growth factor receptor mutants from human lung cancers exhibit enhanced catalytic activity and increased sensitivity to gefitinib", Cancer Res, 67, pp.2325~2330 (2007)
- Zhu JQ, "Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals", Cancer Lett, 265, pp.307~317 (2008)
- Okabe T, "Differential constitutive activation of the epidermal growth factor receptor in non-small cell lung cancer cells bearing EGFR gene mutation and amplification", Cancer Res, 67, pp.2046~2053 (2007)
- Okabayashi Y, "Tyrosines 1148 and 1173 of activated human epidermal growth factor receptors are binding sites of Shc in intact cells", J Biol Chem, 269, pp.18674~18678 (1994)
- Engelman JA, "PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib", Cancer Res, 67, pp.11924~11932 (2007)
- Furuyama K, "Sensitivity and kinase activity of epidermal growth factor receptor (EGFR)exon 19 and others to EGFR-tyrosine kinase inhibitors", Cancer Sci, 104, pp.584~589 (2013)
- Chen LY, "Coexistence of EGFR T790M mutation and common activating mutations in pretreatment non-small cell lung cancer:a systematic review and meta-analysis", Lung Cancer, 94, pp.46~53 (2016)